Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACTICLATE CAP vs ACHROMYCIN V
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-t RNA binding.
Bacteriostatic; binds reversibly to 30S ribosomal subunit, inhibits protein synthesis by blocking aminoacyl-t RNA binding to m RNA-ribosome complex.
Treatment of infections caused by susceptible bacteria, including respiratory tract infections, urinary tract infections, and acne vulgaris
Infections caused by susceptible strains of bacteria including rickettsiae, Mycoplasma pneumoniae, Chlamydia trachomatis, and spirochetes,Acne vulgaris,Adjunctive therapy in severe acne,Off-label: Chronic prostatitis, sclerosing keratitis, rosacea
350 mg orally once daily, increased to 350 mg twice daily if no response after 2 weeks.
250-500 mg orally every 6 hours
Terminal elimination half-life 6-10 hours; prolonged in renal impairment (up to 22 hours in anuria)
Terminal elimination half-life is 6-12 hours in patients with normal renal function; prolonged in renal impairment (up to 48-72 hours in anuria).
Primarily hepatic; metabolites include 4-epimino derivatives; not significantly metabolized via CYP450.
Not extensively metabolized; primarily excreted unchanged in urine via glomerular filtration; small amount metabolized in liver.
Renal (60-70% as unchanged drug), fecal (20-30% as metabolites); minor biliary elimination
Renal (60% unchanged in urine via glomerular filtration), biliary/fecal (40% as active drug and metabolites, with a portion undergoing enterohepatic recirculation).
90-95% bound to serum proteins, primarily albumin
50-65% bound to serum albumin; primarily binds to alpha-1-acid glycoprotein.
0.75 L/kg (50-70 L in adults); distributes well into tissues including bone, teeth, and synovial fluid
1.5-2.0 L/kg (large volume indicates extensive tissue distribution, concentrating in bile, liver, kidneys, and bone; minimal CNS penetration despite lipophilicity).
Oral: 90-100% (capsule); food or dairy reduces absorption by up to 50%
Oral: 60-80% (reduced by food, particularly dairy products, due to chelation with divalent cations). Intravenous: 100%.
e GFR 30-59 m L/min: 350 mg once daily; e GFR <30 m L/min: not recommended.
GFR 50-80 m L/min: no adjustment; GFR 10-50 m L/min: 250-500 mg every 12-24 hours; GFR <10 m L/min: 250-500 mg every 24 hours
Child-Pugh A: no adjustment; Child-Pugh B or C: 175 mg once daily.
No dosage adjustment required; use with caution in severe hepatic impairment due to potential hepatotoxicity
Not established for children <12 years; for ≥12 years, same as adult dosing.
Children >8 years: 25-50 mg/kg/day orally divided every 6 hours
Initiate at 175 mg once daily; titrate cautiously based on renal function.
Consider age-related renal impairment; adjust dose based on GFR; avoid if possible due to increased risk of photosensitivity and gastrointestinal effects
Photosensitivity: severe sunburn can occur with sun exposure; discontinue if photosensitivity occurs. Tooth development: use during tooth development (last half of pregnancy, infancy, childhood to age 8) may cause permanent tooth discoloration. Bone growth: may retard bone growth in premature infants. Renal toxicity: may cause azotemia, hyperphosphatemia, and acidosis. Avoid in renal impairment.
Use during tooth development (last half of pregnancy, infancy, childhood to age 8 years) may cause permanent discoloration of teeth (yellow-gray-brown).
Photosensitivity, tooth discoloration, bone growth retardation, renal impairment, hepatotoxicity, increased intracranial pressure, superinfection, and use in pregnancy/lactation.
Photosensitivity manifested by exaggerated sunburn reaction,Renal impairment may lead to drug accumulation and potential hepatotoxicity,Superinfection with resistant organisms including fungi,Bone growth retardation in premature infants,Pseudotumor cerebri (benign intracranial hypertension) in adults
Hypersensitivity to tetracyclines, pregnancy, breastfeeding, children under 8 years, renal impairment, and concurrent use with oral retinoids.
Hypersensitivity to tetracyclines,Pregnancy,Children under 8 years of age,Severe renal or hepatic impairment
Avoid food and beverages for at least 1 hour before and after administration, as they can reduce the efficacy of activated charcoal. Do not mix with milk or ice cream, as they decrease binding capacity. Administer with water or a non-carbonated, non-alcoholic drink.
Avoid dairy products (milk, cheese, yogurt) and calcium-fortified foods within 2-4 hours of dosing. Also avoid concurrent intake of iron-rich foods or supplements, zinc, magnesium, and antacids. High-fat meals may reduce absorption; take on an empty stomach.
First trimester: Category D; tetracyclines can cause fetal harm including inhibited bone growth and discoloration of teeth (yellow-gray-brown). Second and third trimesters: Known to cause permanent tooth discoloration (enamel hypoplasia) and reversible inhibition of bone growth; use contraindicated after 15 weeks gestation.
Tetracyclines, including ACHROMYCIN V (tetracycline hydrochloride), are classified as FDA Pregnancy Category D. Use during the second and third trimesters may cause permanent tooth discoloration (yellow-gray-brown) and enamel hypoplasia in the fetus. Reversible inhibition of bone growth has been reported. First-trimester exposure is associated with a small risk of neural tube defects and other malformations in some studies. Avoid use during pregnancy unless for serious infections (e.g., anthrax, brucellosis) when alternative antibiotics are contraindicated.
Tetracyclines are excreted in breast milk but absorption by the infant is limited due to chelation with milk calcium; M/P ratio for doxycycline is approximately 0.3-0.4. Theoretical risk of tooth staining and bone inhibition, but clinical significance is low with short-term use; caution with prolonged therapy.
Tetracycline is excreted into human milk in low concentrations. The milk-to-plasma ratio (M/P) is approximately 0.6–0.8. Theoretical risks include dental staining and bone growth inhibition in the nursing infant. Short-term use at recommended doses is generally considered compatible with breastfeeding by the American Academy of Pediatrics, but prolonged or repeated courses should be avoided. Monitor infant for potential gastrointestinal disturbances or rash.
No dosage adjustment is typically recommended for doxycycline in pregnancy due to minimal pharmacokinetic changes; however, use is generally avoided in the second and third trimesters. If indicated, standard dosing may be used in the first trimester with caution.
Pregnancy reduces tetracycline serum concentrations due to increased volume of distribution and enhanced hepatic clearance. However, dose adjustments are not routinely recommended because the drug is generally avoided in pregnancy. If use is unavoidable (e.g., anthrax), standard adult doses (e.g., 250-500 mg every 6 hours) may be insufficient; consider monitoring serum levels if available and adjusting based on clinical response. Avoid in the second and third trimesters if possible.
ACTICLATE CAP is a high-dose activated charcoal formulation used for acute poisoning or overdose. Administer within 1 hour of ingestion for optimal efficacy. Do not use in patients with impaired consciousness unless the airway is protected. Monitor for vomiting and ensure rapid administration via nasogastric tube if necessary. Not effective for alcohols, metals, or caustics.
Tetracycline chelates with divalent and trivalent cations; avoid concurrent administration with dairy, antacids, iron, or calcium supplements. Photosensitivity risk: advise sun avoidance and use of sunscreen. Monitor renal function in elderly; adjust dose in severe renal impairment. Not for use in pregnancy or children under 8 years due to tooth discoloration and bone growth inhibition. Administer on an empty stomach (1 hour before or 2 hours after meals) for optimal absorption.
Take ACTICLATE CAP only if directed by a healthcare professional after a poisoning or overdose.,This medication is not for regular use; it is a one-time emergency treatment.,Avoid taking this with food or drinks; take on an empty stomach for best absorption of toxins.,You may experience black stools or vomiting; this is normal.,Seek immediate medical attention if you have trouble swallowing, severe vomiting, or signs of bowel obstruction.
Take this medication on an empty stomach, at least 1 hour before or 2 hours after meals.,Avoid dairy products, antacids, iron supplements, and calcium supplements within 2-4 hours of taking this drug.,Protect your skin from sun exposure; use sunscreen and wear protective clothing as this medicine can cause severe sunburn.,Do not take this drug if you are pregnant or breastfeeding; it can harm the baby's teeth and bones.,Complete the full course of treatment even if you feel better; do not skip doses.,Report any signs of allergic reaction, severe headache, blurred vision, or persistent diarrhea to your doctor immediately.,Store at room temperature away from moisture and light.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACTICLATE CAP vs ACHROMYCIN V, answered by our medical review team.
ACTICLATE CAP is a Tetracycline Antibiotic that works by Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-t RNA binding.. ACHROMYCIN V is a Tetracycline Antibiotic that works by Bacteriostatic; binds reversibly to 30S ribosomal subunit, inhibits protein synthesis by blocking aminoacyl-t RNA binding to m RNA-ribosome complex.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACTICLATE CAP and ACHROMYCIN V depend on the specific clinical indication. These are both Tetracycline Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACTICLATE CAP is: 350 mg orally once daily, increased to 350 mg twice daily if no response after 2 weeks.. The standard adult dose of ACHROMYCIN V is: 250-500 mg orally every 6 hours. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACTICLATE CAP and ACHROMYCIN V in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACTICLATE CAP is classified as Category C. First trimester: Category D; tetracyclines can cause fetal harm including inhibited bone growth and discoloration of teeth (yellow-gray-brown). Second and third trimesters: Known t. ACHROMYCIN V is classified as Category C. Tetracyclines, including ACHROMYCIN V (tetracycline hydrochloride), are classified as FDA Pregnancy Category D. Use during the second and third trimesters may cause permanent tooth. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.